Astria Therapeutics Inc (ATXS) — Cash Flow-to-Debt Ratio
Astria Therapeutics Inc (ATXS) has a Cash Flow-to-Debt Ratio of -0.84x as of September 2025, meaning its operating cash flow of $-32.30 Million could theoretically repay -1% of its total liabilities ($38.61 Million) in one year. Explore Astria Therapeutics Inc (ATXS) cash conversion ratio to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Astria Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Astria Therapeutics Inc across 13 annual periods. Also explore total assets of Astria Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Astria Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Astria Therapeutics Inc. For market capitalisation and broader financial context, see Astria Therapeutics Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.52x | $-81.21 Million | $23.10 Million | ▲ +40.7% |
| 2023 | -5.93x | $-68.44 Million | $11.55 Million | ▼ -28.2% |
| 2022 | -4.62x | $-43.53 Million | $9.42 Million | ▲ +20.2% |
| 2021 | -5.79x | $-30.15 Million | $5.20 Million | ▼ -21.1% |
| 2020 | -4.79x | $-32.48 Million | $6.79 Million | ▼ -9.2% |
| 2019 | -4.38x | $-26.57 Million | $6.06 Million | ▲ +21.0% |
| 2018 | -5.55x | $-23.46 Million | $4.23 Million | ▼ -26.3% |
| 2017 | -4.40x | $-26.84 Million | $6.11 Million | ▼ -48.8% |
| 2016 | -2.95x | $-32.86 Million | $11.12 Million | ▼ -36.1% |
| 2015 | -2.17x | $-29.79 Million | $13.73 Million | ▼ -846.3% |
| 2014 | -0.23x | $-20.41 Million | $89.02 Million | ▼ -16.6% |
| 2013 | -0.20x | $-16.37 Million | $83.19 Million | ▲ +97.4% |
| 2012 | -7.69x | $-15.58K | $2.03K | — |